Form 4: AN2 Therapeutics CDO Sells Shares for Tax Obligations

AN2 Therapeutics' Chief Development Officer, Sanjay Chanda, sold shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Sanjay Chanda, Chief Development Officer of AN2 Therapeutics, Inc. (ANTX), sold a total of 9,251 shares of common stock on January 5 and January 6, 2026.
• These sales were executed to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs) on January 1, 2026.
• The sales occurred at prices of $1.003 per share for 3,295 shares and $1.012 per share for 5,956 shares.
• Following these transactions, Mr. Chanda beneficially owns 75,823 shares of common stock.
• His beneficial ownership includes 27,500 RSUs vesting annually over four years from January 1, 2024, and 50,250 RSUs vesting annually over four years from January 1, 2025.
• The reported total also accounts for the purchase of 5,000 shares under the company's Employee Stock Purchase Plan on September 30, 2025.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The filing reports routine insider transactions, specifically sales to cover tax obligations from RSU vesting, which are generally neutral. The executive's participation in the ESPP and continued RSU holdings are mildly positive, indicating ongoing alignment with shareholder interests, but the sales themselves are a slight reduction in direct stake.

Positives

• The vesting of Restricted Stock Units (RSUs) indicates continued long-term incentive for the Chief Development Officer.
• Participation in the Employee Stock Purchase Plan (ESPP) by the Chief Development Officer suggests confidence in the company's future.

Negatives

• The sale of 9,251 shares by a key executive, even for tax purposes, reduces their direct equity stake in the company.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Industry Context

This filing reports routine insider transactions for a specific executive and does not provide information relevant to broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership, but the sales are for tax purposes and pre-planned, so unlikely to signal a lack of confidence. Continued RSU holdings and ESPP participation suggest ongoing alignment.
• Employees: No direct impact on employees, but the RSU vesting and ESPP demonstrate standard executive compensation practices.

Next Steps

• Continued vesting of 27,500 RSUs annually over four years from January 1, 2024.
• Continued vesting of 50,250 RSUs annually over four years from January 1, 2025.

Key Dates

Recommendation

This Form 4 details routine insider transactions where the Chief Development Officer sold shares to cover tax obligations from RSU vesting, a common and expected event. The transactions were pre-planned under a Rule 10b5-1(c) plan, mitigating any negative signal. The executive also purchased shares via an ESPP and retains significant RSU holdings, indicating continued alignment with the company's long-term prospects. There is no new material information in this filing to warrant a change in investment thesis; therefore, a 'hold' recommendation is appropriate.

Keywords

AN2 Therapeutics, ANTX, Sanjay Chanda, Form 4, Insider Trading, Stock Sale, RSU Vesting, Tax Withholding, Employee Stock Purchase Plan, ESPP, Chief Development Officer, Equity Compensation